Harnessing RNA-Seq for Advancing DDR Inhibitor Therapies
Time: 9:00 am
day: Day One
Details:
- Analyzing tumor gene expression to uncover critical insights into cellular composition, tumor origin, and the tumor microenvironment (TME), including biomarkers that indicate therapeutic response
- Applying these insights at every stage of drug development, from target discovery and mechanistic studies to clinical trial design, patient recruitment, and biomarker validation
- Identifying biomarkers that inform dosing strategies and assess potential toxicity in DDR inhibitor therapies
